Invesco India Pharma and Healthcare Fund vs Nippon India Pharma Fund
Direct Plan, Growth option · Data as on 30-10-2026
Invesco India Pharma and Healthcare Fund is a Sectoral fund and Nippon India Pharma Fund is a Sectoral fund. Invesco India Pharma and Healthcare Fund charges 3.30% a year and Nippon India Pharma Fund 0.99% (Direct plans). Their portfolios overlap 27.6%: they hold 5 of the same securities.
Invesco India Pharma and Healthcare Fund
Sectoral
- Expense ratio
- 3.30%
- NAV
- ₹9.66
Which is better, Invesco India Pharma and Healthcare or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Nippon India Pharma costs less: 0.99% a year against 3.30% (Direct plans).
- Nippon India Pharma fell less in its worst fall since 10-09-2026: −9.1% against −11.4%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹436 Cr.
- Their portfolios overlap 27.6%: 5 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Invesco India Pharma and Healthcare Fund | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Invesco Mutual Fund | Nippon India Mutual Fund |
| Category | Sectoral | Sectoral |
| AUM | ₹436 Cr (30-09-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹9.66 (Direct) | ₹625.46 (Direct) |
| Expense ratio (Direct) | 3.30% | 0.99% |
| Expense ratio (Regular) | 5.19% | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 01-09-2026 | 05-06-2004 |
| Minimum investment | Not available | ₹5,000 |
| Lock in | None | None |
| Fund managers | Aditya Khemani | Sailesh Raj Bhan |
| Exit load | Exit load of 0.50%, if redeemed within 3 months. | Exit load of 1% if redeemed within 1 month. |
Invesco India Pharma and Healthcare vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Invesco India Pharma and Healthcare Fund (Direct) | +0.73% | -- | -- | -- | -- | -- | -- |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 20 Sectoral funds, same plan type.
Invesco India Pharma and Healthcare vs Nippon India Pharma: Year-wise Returns
| Year | Invesco India Pharma and HealthcareInvesco India Pharma and Healthcare | Nippon India PharmaNippon India Pharma | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | -- | +9.76% | +15.08% |
| 2025 | -- | −2.46% | −2.72% |
| 2024 | -- | +35.26% | +44.30% |
| 2023 | -- | +40.36% | +37.97% |
| 2022 | -- | −9.06% | −11.50% |
| 2021 | -- | +25.12% | +21.54% |
Invesco India Pharma and Healthcare vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Invesco India Pharma and Healthcare vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Invesco India Pharma and Healthcare Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | −23.45% | +17.18% |
| Standard deviation | 18.70% | 15.19% |
| Sharpe ratio | -1.54 | 0.73 |
| Sortino ratio | -2.20 | 1.06 |
| Maximum drawdown | −11.4% (23-10-2026) | −24.0% (29-05-2017) |
| Beta | 1.00 | 0.85 |
| Alpha | −8.00% | +3.72% |
From daily NAVs, 10-09-2026 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Invesco India Pharma and Healthcare Fund (Direct)
Nippon India Pharma Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Invesco India Pharma and Healthcare Fund (Direct) | −11.4% | 23-09-2026 | 23-10-2026 | Not yet | -- | −4.4% |
| Nippon India Pharma Fund (Direct) | −9.1% | 23-09-2026 | 23-10-2026 | Not yet | -- | −3.9% |
| BSE Healthcare TRI | −9.9% | 23-09-2026 | 23-10-2026 | Not yet | -- | −3.8% |
From daily values since 10-09-2026, the first day every fund has.
Invesco India Pharma and Healthcare vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: Invesco India Pharma and Healthcare Fund, September 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 27.6%
- Held by both
- 5
- Only in Invesco India Pharma and Healthcare
- 8
- Only in Nippon India Pharma
- 31
| Security | % of Invesco India Pharma and Healthcare | % of Nippon India Pharma |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 8.99% | 11.71% |
| Divi's Laboratories Limited | 7.85% | 7.10% |
| Apollo Hospitals Enterprise Limited | 8.03% | 4.89% |
| Sai Life Sciences Limited | 8.63% | 3.92% |
| Max Healthcare Institute Limited | 9.58% | 2.70% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 27.6% means 27.6% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Invesco India Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Manipal Health Enterprises Ltd | 7.98% |
| Global Health Limited | 7.00% |
| Dr Agarwals Health Care Limited | 6.32% |
| Corona Remedies Limited | 6.13% |
| Torrent Pharmaceuticals Limited | 4.93% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| Lupin Limited | 6.17% |
| Cipla Limited | 6.01% |
| Dr. Reddy's Laboratories Limited | 5.45% |
| Mankind Pharma Limited | 4.38% |
| Ajanta Pharma Limited | 3.61% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Invesco India Pharma and Healthcare | Nippon India Pharma |
|---|---|---|
| Equity | 87.0% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | 13.0% | 2.7% |
Market cap of stocks
| Market cap | Invesco India Pharma and Healthcare | Nippon India Pharma |
|---|---|---|
| Large Cap | 29.8% | 29.7% |
| Mid Cap | 16.4% | 39.0% |
| Small Cap | 32.8% | 28.0% |
| Not on AMFI's list | 8.0% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Invesco India Pharma and Healthcare | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 41.4% | 74.0% |
| Healthcare Services | 45.6% | 20.3% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 0.0% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Invesco India Pharma and Healthcare vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Invesco India Pharma and Healthcare Fund | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | 3.30% | 0.99% |
| Base expense ratio (Direct) | 0.50% | 0.79% |
| Total expense ratio (Regular) | 5.19% | 1.85% |
| Base expense ratio (Regular) | 2.10% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Invesco India Pharma and Healthcare with
Invesco India Pharma and Healthcare Fund vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between Invesco India Pharma and Healthcare Fund and Nippon India Pharma Fund?
Invesco India Pharma and Healthcare Fund is a Sectoral fund, Nippon India Pharma Fund is a Sectoral fund, run by Invesco Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 27.6%. Invesco India Pharma and Healthcare Fund charges 3.30% a year and Nippon India Pharma Fund 0.99%.
Which has the lower expense ratio, Invesco India Pharma and Healthcare Fund or Nippon India Pharma Fund?
Nippon India Pharma Fund charges less: 0.99% a year against 3.30%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Invesco India Pharma and Healthcare Fund and Nippon India Pharma Fund overlap?
27.6%. They hold 5 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, APOLLOHOSP. From each fund's latest monthly portfolio.
Which is riskier, Invesco India Pharma and Healthcare Fund or Nippon India Pharma Fund?
On SEBI's riskometer, Invesco India Pharma and Healthcare Fund is rated Very High and Nippon India Pharma Fund Very High. Over their common history, the standard deviation of daily returns was 18.70% and 15.19% a year.
Can I invest in both Invesco India Pharma and Healthcare Fund and Nippon India Pharma Fund?
Yes. 27.6% of each fund's money sits in the same holdings, so some of the two investments would move together.
Who manages Invesco India Pharma and Healthcare Fund and Nippon India Pharma Fund?
Invesco India Pharma and Healthcare Fund: Aditya Khemani. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.